U.S. PTAB rules ShockWave's claims of '091 patent 'unpatentable' » 15:4607/0807/08/20
The U.S. Patent Trial and…
The U.S. Patent Trial and Appeal Board, or PTAB, ruled against ShockWave Medical (SWAV) in IPR2019-00409: Cardiovascular Systems (CSII) v. Shockwave Medical - U.S. Patent No. 8728091, Shockwave Catheter System With Energy Control. The ruling stated that "Cardiovascular Systems has shown, by a preponderance of the evidence, that claims 1-14 of patent 8,728,091 are unpatentable."
|Over a week ago|
Cardiovascular Systems initiated with a Buy at Aegis » 11:1606/1906/19/20
Earlier, Aegis analyst…
Earlier, Aegis analyst Nathan Weinstein initiated coverage of Cardiovascular Systems with a Buy rating and $45 price target.
Piper Sandler to hold a virtual event » 10:0006/1606/16/20
CSII, INSP, KIDS, TCMD
Midwest Medtech Day…
Midwest Medtech Day Virtual Event will be held on June 16.
|Over a month ago|
Fly Intel: Top five analyst upgrades » 10:0906/1106/11/20
AAPL, KDP, CSII, KL, SWAV
Catch up on today's…
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Apple (AAPL) upgraded to Hold from Reduce at HSBC WITH analyst Nicolas Cote-Colisson saying he expects a successful launch of a 5G iPhone in the third quarter of 2020. 2. Keurig Dr Pepper (KDP) upgraded to Buy from Hold at Jefferies with analyst Kevin Grundy saying he groups Keurig Dr Pepper as among the beneficiaries from the work-from-home trend given it has a higher share in the at-home channels. 3. Cardiovascular Systems (CSII) upgraded to Buy from Hold at Needham with analyst Mike Matson saying the company can "resume and sustain" double-digit revenue growth post-COVID-19, driven by new products and geographic expansion. 4. Kirkland Lake Gold (KL) upgraded to Buy from Neutral at Roth Capital with analyst Jake Sekelsky saying with the backdrop of the U.S. entering a recession, increased government spending resulting from the COVID-19 pandemic, interest rates at or possibly below zero, and U.S. unemployment over 13%, precious metals are poised for a "bull cycle" similar to the one seen following the 2008 financial crisis. 5. ShockWave Medical (SWAV) upgraded to Perform from Underperform at Oppenheimer with analyst Suraj Kalia saying consistent with the broader market, ShockWave has rallied about 40% since early April, and now trades at 15-times fiscal year 2021 P/S, one of the highest valuations in med tech-land. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
Needham upgrades Cardiovascular Systems on 'too compelling' valuation » 05:3806/1106/11/20
Needham analyst Mike…
Needham analyst Mike Matson upgraded Cardiovascular Systems to Buy from Hold with a $44 price target. The company can "resume and sustain" double-digit revenue growth post-COVID-19, driven by new products and geographic expansion, Matson tells investors in a research note. Further, the analyst views the consensus estimates for fiscal 2021 and 2022, which are well below his estimates, as conservative. Matson says that while reimbursement represents an overhang and headline risk, he does not expect any changes for several years. Further, Cardiovascular's recent equity offering strengthens its balance sheet and provides it with increased flexibility, adds the analyst. The stock's valuation has become "too compelling to ignore," contends Matson.
Cardiovascular Systems upgraded to Buy from Hold at Needham » 05:3306/1106/11/20
Needham analyst Michael…
Needham analyst Michael Matson upgraded Cardiovascular Systems to Buy from Hold with a $44 price target.
Fly Intel: Pre-market Movers » 09:0306/1006/10/20
GMAB, FULC, TRUE, DUO, LAKE, UNFI, RRGB, CMCM, GME, SBUX, SALT, CSII
Check out this morning's…
Cardiovascular Systems 3.676M share Spot Secondary priced at $34.00 » 06:1906/1006/10/20
The deal range was…
The deal range was $33.00-$35.00. Barclays and SVB Leerink acted as joint book running managers for the offering.
Cardiovascular Systems files to sell $125M in common stock » 16:1006/0906/09/20
Barclays and SVB Leerink…
Barclays and SVB Leerink are acting as joint book-running managers for the offering.
Cardiovascular Systems price target lowered to $48 from $54 at Lake Street » 08:4105/0605/06/20
Lake Street analyst…
Lake Street analyst Brooks O'Neil lowered the firm's price target on Cardiovascular Systems to $48 from $54 as he lowered his forecast to reflect the elevated impact Of COVID-19 after the company reported lower than expected Q3 revenues. While disruption of procedure volume and delays in inventory restocking turned out to have a greater impact than he'd expected, O'Neil keeps a Buy rating on Cardiovascular Systems shares as he has "high confidence" in the company's ability to continue to effectively operate and "adequate liquidity to weather the COVID-19 storm."